HIGHBuilt-in & outside partyCustomer
U.S. Government (USG)
“10-K Item 1A: 'The USG is the principal customer for our MCMs and the primary source of funds for the development of most of our product candidates in our development pipeline.'”
EBS · Concentration risk · 10-K extracted
Emergent BioSolutions (EBS) concentration risks
Updated
The most significant concentration Emergent BioSolutions discloses is U.S. Government (USG), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Emergent BioSolutions’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
sole-source suppliers
“10-K Item 1A: 'The loss of sole-source suppliers or an increase in the price of inventory.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Emergent BioSolutions' concentration risk runs through both ends of its business model. On the revenue side, the U.S. Government is the principal customer for its medical countermeasures and the primary source of funding for most of its pipeline — a high-share exposure the company itself frames as mixed in character, reflecting both the relative stability of a government relationship and the budgetary/contracting risk that comes with depending on a single payer. On the supply side, Emergent faces the loss of sole-source suppliers or price increases on inventory as a distinct risk, also disclosed at a high share. These two exposures sit at opposite ends of the value chain but reinforce each other: a company this dependent on one government customer has limited ability to absorb a simultaneous supply disruption, since neither exposure can be offset by diversifying into other markets in the near term. Both are described at a high disclosed share, meaning neither should be read as minor, and together they define a business whose commercial and operational risk is concentrated rather than diversified.
For the engine’s reasoning on EBS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| EBS● | Emergent BioSolutions Inc. | 2 | 0 | 0 | 2 |
| AMPH | Amphastar Pharmaceuticals, Inc. | 1 | 2 | 1 | 4 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.